PART I . Overview CNS Pharmaceuticals, Inc. (CNS, the Company, we, us, or our) is a biotechnology company focused on developing innovative therapies for serious diseases in neurology and oncology. Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical spending, encompass some of the most prevalent and difficult to treat diseases affecting humanity, and are characterized by significant unmet medical need. Significant progress has been made in t...
Q2 FY2026 — expected 2026-07-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001683168-26-002550 | EDGAR | 43K words |
| 2025-03-31 | 2024-12-31 | 0001683168-25-002139 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0001683168-24-002032 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001683168-23-002086 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0001683168-22-001401 | EDGAR | — |
| 2021-02-12 | 2020-12-31 | 0001683168-21-000533 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001683168-20-000781 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-12 | 2026-06-30 | 0001683168-26-006224 | EDGAR | — |
| 2025-11-14 | 2025-09-30 | 0001683168-25-008466 | EDGAR | 14K words |
| 2025-08-14 | 2025-06-30 | 0001683168-25-006162 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0001683168-25-003733 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001683168-24-008125 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001683168-24-005711 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0001683168-24-003531 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001683168-23-008144 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001683168-23-005609 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001683168-23-003311 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001683168-22-007532 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001683168-22-005637 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-11 | 0001683168-26-001664 | EDGAR | 1K words |
| 2026-03-02 | 0001683168-26-001413 | EDGAR | — |
| 2026-02-17 | 0001683168-26-001066 | EDGAR | — |
| 2025-12-17 | 0001683168-25-009208 | EDGAR | — |
| 2025-11-21 | 0001683168-25-008624 | EDGAR | — |
| 2025-07-22 | 0001683168-25-005284 | EDGAR | — |
| 2025-07-15 | 0001683168-25-005129 | EDGAR | — |
| 2025-05-15 | 0001683168-25-003575 | EDGAR | — |
| 2025-04-09 | 0001683168-25-002373 | EDGAR | — |
| 2025-03-31 | 0001683168-25-002140 | EDGAR | — |
169 total filings indexed. 140 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001729427 |
| Ticker | CNSP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.cnspharma.com |
| Listed | 2019-11-08 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CNSP (~200 tokens, structured JSON with cryptographic provenance)